Prothena Co. plc (NASDAQ:PRTA - Free Report) - Investment analysts at Zacks Research boosted their Q1 2025 earnings estimates for shares of Prothena in a research report issued to clients and investors on Wednesday, March 12th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings of ($1.06) per share for the quarter, up from their previous forecast of ($1.33). The consensus estimate for Prothena's current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena's Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($3.76) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.28) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($4.04) EPS.
Several other equities research analysts have also weighed in on the stock. StockNews.com raised shares of Prothena from a "sell" rating to a "hold" rating in a report on Monday, February 24th. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 target price on shares of Prothena in a report on Friday, February 21st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Prothena in a research report on Friday, February 21st. Bank of America reduced their price target on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a research report on Thursday, December 19th. Finally, Oppenheimer upped their price target on shares of Prothena from $58.00 to $62.00 and gave the stock an "outperform" rating in a research report on Friday, February 7th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Prothena currently has an average rating of "Moderate Buy" and an average target price of $55.00.
Check Out Our Latest Stock Analysis on PRTA
Prothena Price Performance
Shares of PRTA traded up $0.01 during trading hours on Monday, hitting $12.89. The stock had a trading volume of 199,025 shares, compared to its average volume of 483,338. The company's fifty day moving average is $14.35 and its two-hundred day moving average is $15.96. Prothena has a 52 week low of $11.70 and a 52 week high of $26.45. The stock has a market capitalization of $693.78 million, a price-to-earnings ratio of -5.58 and a beta of -0.02.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.06). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.12 million during the quarter, compared to the consensus estimate of $7.53 million.
Hedge Funds Weigh In On Prothena
Several hedge funds have recently made changes to their positions in PRTA. Virtus ETF Advisers LLC grew its stake in shares of Prothena by 19.3% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock worth $71,000 after acquiring an additional 833 shares in the last quarter. Headlands Technologies LLC grew its stake in shares of Prothena by 196.5% during the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company's stock worth $102,000 after acquiring an additional 4,858 shares in the last quarter. Teacher Retirement System of Texas bought a new position in shares of Prothena during the 4th quarter worth approximately $145,000. Purkiss Capital Advisors LLC acquired a new stake in shares of Prothena in the 4th quarter valued at approximately $149,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Prothena by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,409 shares of the biotechnology company's stock valued at $158,000 after buying an additional 1,065 shares during the last quarter. 97.08% of the stock is owned by institutional investors.
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Read More
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
